세계의 흑색종 치료제 시장

Highlights:

The global market for melanoma therapeutics is estimated to increase from $7.4 billion in 2023 to reach $12.1 billion by 2028, at a compound annual growth rate (CAGR) of 10.2% from 2023 through 2028.

North American market for melanoma therapeutics is estimated to increase from $3.5 billion in 2023 to reach $5.8 billion by 2028, at a compound annual growth rate (CAGR) of 11.0% from 2023 through 2028.

European market for melanoma therapeutics is estimated to increase from $2.3 billion in 2023 to reach $3.8 billion by 2028, at a compound annual growth rate (CAGR) of 10.1% from 2023 through 2028.

Report Scope:

This study investigates the melanoma treatment market. BCC Research analyzes melanoma treatment based on treatment type, cancer stage and type of therapeutics. BCC determines the current market status in each segment, examines its impact on future needs and presents growth forecasts over the next five years. The report provides a detailed analysis of the market's drivers, challenges, and opportunities. The report also covers market projections through 2028 and analyzes market share for key market players. In its profiles of key companies, the report provides detailed information about their business segments, financials, product portfolios and recent developments. The report also discusses the market impact of the COVID-19 pandemic, emerging technologies, and new developments, ESG development and investment outlook.

Report Includes:

• 30 data tables and 18 additional tables
• An overview of the global market for melanoma treatment
• Analyses of global market trends, with data from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
• Description of various treatment options such as chemotherapy, surgical resection, immunotherapy, and targeted therapies; and various treatment approaches for the betterment of patient's overall health
• A look at the advancements in the genetic profiling of melanocytes and identification of novel molecules that involved in melanoma's development
• Information on new potential therapeutic target discovery; and description of novel immune checkpoint inhibitors, adoptive cell therapy and engineered TCR therapy
• Coverage of innovation, technological advancements, and the launch of novel products from market players
• Detailed analysis of the regulatory framework and policies and product pipeline of the industry, and discussion on ESG challenges in the pharmaceutical industry and ESG practices in the melanoma treatment market
• Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies and a relevant patent analysis
• Comprehensive company profiles of the leading players of the industry, including Amgen, Roche, Merck & Co., Pfizer Inc., BMS, and Novartis AG

Table of Contents

Chapter 1 Introduction

• Study Goals and Objectives
• Scope of the Report
• Reasons for Doing the Study
• Methodology
• Information Sources
• Geographic Breakdown
• Segmentation Breakdown

Chapter 2 Summary and Highlights

• Market Outlook
• Market Summary

Chapter 3 Market and Technology Background

• Introduction
• Risk Factors, Causes and Prevention
• Symptoms
• Pathophysiology and Clinical Subtypes
• Prognosis
• Epidemiology
• Diagnosis
• Biopsy
• Laboratory Tests
• Blood Tests
• Imaging Tests
• Treatment
• Immunotherapy
• PD-1 and PD-L1 Inhibitors
• CTLA-4 inhibitors
• LAG-3 Inhibitors
• Interleukin-2 (IL-2, Proleukin)
• Virus Therapy
• BRAF inhibitors:
• MEK Inhibitors

Chapter 4 Market Dynamics

• Market Factors
• Market Drivers
• Increasing Prevalence of Melanoma
• Technological Advancements and Product Launches
• Strategic Initiatives
• Developments in Early Detection Tools
• Patient Advocacy Groups and Awareness
• Market Restraints
• High Cost of Treatment
• Stringent Regulations
• Resistance to Therapies
• Market Opportunities

Chapter 5 Market Breakdown by Type

• Overview
• Surgery
• Wide Excision
• Mohs Surgery
• Amputation
• Lymph Node Dissection
• Therapeutics
• Therapeutics by Type
• Radiation Therapy

Chapter 6 Market Breakdown by Disease Stage

• Overview
• Localized Disease
• Regional Disease
• Distant Disease

Chapter 7 Market Breakdown by Region

• Overview
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 8 Sustainability: An ESG Perspective

• Introduction
• ESG Challenges in the Pharmaceutical Industry
• ESG Practices in the Market for Melanoma Therapeutics
• Environmental Initiatives
• Social Initiatives
• Governance Initiatives
• Case Study
• BCC Research Viewpoint

Chapter 9 Emerging Technologies/ Developments

• Introduction
• Novel Immune Checkpoint Inhibitors
• Adoptive Cell Therapy
• Engineered TCR Therapy
• Vaccines
• Targeted Therapy

Chapter 10 Regulatory Landscape and Pipeline Analysis

• Regulatory Landscape
• United States
• Europe
• Japan
• Pipeline Analysis

Chapter 11 Patent Analysis

• Patent Review by Year
• Patent Review by Country
• Patent Review

Chapter 12 Competitive Landscape

• Mergers and Acquisitions
• Strategic Initiatives
• Competitive Analysis

Chapter 13 Company Profiles

• AMGEN INC.
• ASTRAZENECA PLC
• BRISTOL-MYERS SQUIBB
• ERASCA INC.
• F. HOFFMANN-LA ROCHE AG
• HUYABIO INTERNATIONAL
• IOVANCE BIOTHERAPEUTICS INC.
• IO BIOTECH
• MERCK & CO. INC.
• MODERNA INC.
• NOVARTIS AG
• PFIZER INC.
• REGENERON PHARMACEUTICALS INC.